About the Webinar
The market for oligonucleotide therapeutics is growing, with several drugs already approved and many more in development, offering a promising avenue for targeted therapies. However, oligonucleotide therapies targeting microRNA (miRNA) are yet to be successful.
In this webinar, our expert speaker will explore the therapeutic potential of miRNA- targeting treatments, outlining cutting-edge research that is identifying new miRNA targets.
He’ll also discuss the latest methodologies in miRNA research, including next-generation sequencing and miRNA inhibition.
This webinar covers:
- A brief history of oligonucleotide therapeutics, from routine failure to routine success
- Why oligonucleotide therapeutics targeting miRNAs have not yet been successful
- Nuclear RNA interference as a new approach to identifying therapeutic target miRNAs
Meet the Speaker
David Corey
UT Southwestern University
Dr. Corey received his BA from Harvard University in 1985 and his PhD from UC Berkeley in 1990 after working under the guidance of Dr. Peter Schultz. After postdoctoral work at UCSF under the direction of Dr. Charles Craik, Dr. Corey started his independent career at UT Southwestern in 1992. Dr. Corey is the Rusty Kelley Professor of Biomedical Research and the Past-President of the Oligonucleotide Therapeutics Society. He is an Executive Editor for Nucleic Acids Research and Vice Chair of the SAB for the Ono Pharma Foundation.
If the webinar has not loaded above, please follow the link here.
